- Home
- FHI vs MRUS Comparison
FHI vs MRUS Comparison
Compare FHI & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHI
- MRUS
- Stock Information
- Founded
- FHI 1955
- MRUS 2003
- Country
- FHI United States
- MRUS Netherlands
- Employees
- FHI N/A
- MRUS N/A
- Industry
- FHI Investment Managers
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- FHI Finance
- MRUS Health Care
- Exchange
- FHI Nasdaq
- MRUS Nasdaq
- Market Cap
- FHI 3.2B
- MRUS 2.7B
- IPO Year
- FHI N/A
- MRUS 2016
- Fundamental
- Price
- FHI $36.88
- MRUS $38.11
- Analyst Decision
- FHI Hold
- MRUS Strong Buy
- Analyst Count
- FHI 6
- MRUS 13
- Target Price
- FHI $42.00
- MRUS $86.85
- AVG Volume (30 Days)
- FHI 1.2M
- MRUS 784.4K
- Earning Date
- FHI 04-24-2025
- MRUS 05-07-2025
- Dividend Yield
- FHI 3.36%
- MRUS N/A
- EPS Growth
- FHI N/A
- MRUS N/A
- EPS
- FHI 3.23
- MRUS N/A
- Revenue
- FHI $1,632,093,000.00
- MRUS $36,133,000.00
- Revenue This Year
- FHI $7.96
- MRUS $26.81
- Revenue Next Year
- FHI $4.31
- MRUS $23.85
- P/E Ratio
- FHI $11.42
- MRUS N/A
- Revenue Growth
- FHI 1.40
- MRUS N/A
- 52 Week Low
- FHI $31.24
- MRUS $36.46
- 52 Week High
- FHI $43.92
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- FHI 33.65
- MRUS 34.46
- Support Level
- FHI $40.00
- MRUS $38.40
- Resistance Level
- FHI $41.35
- MRUS $43.58
- Average True Range (ATR)
- FHI 0.86
- MRUS 2.73
- MACD
- FHI -0.24
- MRUS -0.96
- Stochastic Oscillator
- FHI 1.81
- MRUS 12.34
Stock Price Comparison Chart: FHI vs MRUS
About FHI Federated Hermes Inc.
ederated provides asset management services for institutional and individual investors. The company had $757.6 billion in managed assets at the end of December 2023, composed of equity (10%), multi-asset (less than 1%), fixed-income (13%), alternative (3%), and money market (74%) funds. That said, the firm's cash-management operations are expected to generate around 46% of Federated's revenue this year, compared with 29%, 13%, and 11%, respectively, for the firm's equity, fixed-income, and alternatives/multi-asset operations. From a channel perspective, the company's products are distributed via trust banks, wealth managers and retail broker/dealers (63% of AUM), institutional investors (28%), and international clients (9%).
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.